As of 5 Jul 2026, Solara Active Pharma Sci share price is ₹575.85. The stock opened at ₹576.00, compared to its previous close of ₹571.95. During today's trading session, Solara Active Pharma Sci share price moved in the range of ₹572.10 to ₹583.95, with an average price of ₹578.03 for the day. Looking at its last 52-week, the stock has touched a low of ₹422.00 and a high of ₹734.40. On the performance front, Solara Active Pharma Sci share price has declined by 1.07% over the last six months and is down 9.55% on a year-on-year basis.
| Name | Mkt Cap Cr | P/E | P/B | ROE | D/E | ROCE | Book Value | Div. Yield | Turnover | EPS(TTM) |
|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | 4,49,048.00 | 39.02 | 5.37 | 13.74% | 0.61 | 17.33% | 93.24 | 0.85% | 0.56 | 10.90 |
| Divis Laboratories | 1,77,179.00 | 69.00 | 10.57 | 15.32% | 0.00 | 19.56% | 629.49 | 0.45% | 0.58 | 98.19 |
| Torrent Pharmaceuticals | 1,57,804.00 | 66.03 | 17.03 | 26.76% | 1.05 | 18.30% | 16.90 | 0.90% | 0.49 | 64.75 |
| Cipla | 1,17,642.00 | 25.47 | 2.87 | 11.79% | 0.00 | 15.66% | 2.89 | 1.06% | 0.49 | 43.52 |
| Dr. Reddy's Laboratories | 1,12,368.00 | 27.03 | 2.97 | 11.07% | 0.18 | 12.54% | 375.78 | 0.59% | 0.63 | 38.68 |
| Zydus Lifesciences | 1,10,651.00 | 21.60 | 4.08 | 18.59% | 0.31 | 17.35% | 235.25 | 0.09% | 0.39 | 35.38 |
| Lupin | 1,09,676.00 | 20.48 | 4.89 | 23.76% | 0.04 | 24.88% | 659.05 | 0.75% | 0.61 | 129.18 |
| Mankind Pharma | 1,02,729.00 | 53.00 | 6.30 | 11.74% | 0.34 | 13.13% | 397.02 | 0.04% | 0.54 | 49.37 |
| Aurobindo Pharma | 90,608.00 | 25.87 | 2.39 | 9.25% | 0.19 | 11.76% | 391.14 | 0.26% | 0.48 | 41.58 |
| Laurus Labs | 82,398.90 | 60.26 | 10.10 | 18.21% | 0.45 | 16.70% | 10.19 | 0.20% | 0.97 | 13.72 |
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Revenue | ₹1,283.76 | ₹1,288.92 | ₹1,443.81 | ₹1,268.34 |
| Other Income | ₹8.32 | ₹5.37 | ₹22.55 | ₹20.02 |
| Total Revenue | ₹1,292.08 | ₹1,294.29 | ₹1,466.36 | ₹1,288.36 |
| Total Expenses | ₹1,291.54 | ₹1,592.54 | ₹1,511.18 | ₹1,375.97 |
| Profit Before Tax | ₹0.54 | -₹488.42 | -₹44.82 | -₹91.10 |
| Tax | ₹0.00 | ₹78.54 | -₹22.57 | -₹32.81 |
| Profit After Tax | ₹0.54 | -₹566.96 | -₹22.25 | -₹58.29 |
| EPS - Basic | ₹0.14 | -₹148.51 | -₹6.16 | -₹16.18 |
| EPS - Diluted | ₹0.14 | -₹148.51 | -₹6.16 | -₹16.18 |
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Profit before tax | ₹0.54 | -₹488.42 | -₹44.82 | -₹91.10 |
| Income before WC changes | ₹210.70 | -₹82.66 | ₹141.97 | ₹89.86 |
| Change in Assets | ₹51.59 | ₹170.45 | -₹13.16 | -₹324.62 |
| Change in Liabilities | -₹48.57 | ₹20.18 | ₹13.90 | ₹10.83 |
| Change in WC | ₹3.02 | ₹190.63 | ₹0.74 | -₹313.79 |
| Cash flow from Operations | ₹212.82 | ₹108.87 | ₹156.25 | -₹242.03 |
| Cash flow from Investing | -₹36.83 | -₹3.51 | -₹81.14 | -₹242.85 |
| Cash flow from Financing | -₹180.48 | -₹105.65 | -₹112.76 | ₹333.57 |
| Total Cash Flow | -₹4.49 | -₹0.29 | -₹37.65 | -₹151.31 |
| Cash (Start of the year) | ₹8.44 | ₹8.73 | ₹46.38 | ₹197.69 |
| Cash (End of the year) | ₹3.95 | ₹8.44 | ₹8.73 | ₹46.38 |
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Non-Current Assets | ₹1,503.11 | ₹1,550.21 | ₹1,711.74 | ₹1,705.68 |
| Current Assets | ₹728.73 | ₹800.75 | ₹1,187.54 | ₹1,239.28 |
| Total Assets | ₹2,231.84 | ₹2,350.96 | ₹2,899.28 | ₹2,944.96 |
| Current Liabilities | ₹944.11 | ₹1,242.85 | ₹1,101.13 | ₹1,063.42 |
| Net Current Asset | -₹215.38 | -₹442.10 | ₹86.41 | ₹175.86 |
| Non-Current Liabilities | ₹190.82 | ₹171.53 | ₹295.70 | ₹354.36 |
| Equity Capital | ₹1,096.91 | ₹936.58 | ₹1,502.45 | ₹1,527.18 |
| Total Equity & Liabilities | ₹2,231.84 | ₹2,350.96 | ₹2,899.28 | ₹2,944.96 |
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Revenue | ₹1,283.76 | ₹1,288.92 | ₹1,443.81 | ₹1,268.34 |
| Other Income | ₹9.14 | ₹5.37 | ₹22.14 | ₹18.76 |
| Total Revenue | ₹1,292.90 | ₹1,294.29 | ₹1,465.95 | ₹1,287.10 |
| Total Expenses | ₹1,293.98 | ₹1,592.98 | ₹1,510.73 | ₹1,375.27 |
| Profit Before Tax | -₹1.08 | -₹488.33 | -₹44.78 | -₹91.66 |
| Tax | ₹0.00 | ₹78.54 | -₹22.57 | -₹33.10 |
| Profit After Tax | -₹1.08 | -₹566.87 | -₹22.21 | -₹58.56 |
| EPS - Basic | -₹0.27 | -₹148.38 | -₹6.17 | -₹16.29 |
| EPS - Diluted | -₹0.27 | -₹148.38 | -₹6.17 | -₹16.29 |
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Profit before tax | -₹1.08 | -₹488.33 | -₹44.78 | -₹91.66 |
| Income before WC changes | ₹211.08 | -₹82.54 | ₹142.10 | ₹90.32 |
| Change in Assets | ₹51.51 | ₹172.46 | -₹15.71 | -₹324.49 |
| Change in Liabilities | -₹48.89 | ₹20.11 | ₹16.07 | ₹10.45 |
| Change in WC | ₹2.62 | ₹192.57 | ₹0.36 | -₹314.04 |
| Cash flow from Operations | ₹212.80 | ₹110.95 | ₹156.17 | -₹241.77 |
| Cash flow from Investing | -₹36.83 | -₹4.66 | -₹81.13 | -₹243.08 |
| Cash flow from Financing | -₹180.48 | -₹106.52 | -₹112.76 | ₹333.59 |
| Total Cash Flow | -₹4.51 | -₹0.23 | -₹37.72 | -₹151.26 |
| Cash (Start of the year) | ₹8.32 | ₹8.55 | ₹46.27 | ₹197.53 |
| Cash (End of the year) | ₹3.81 | ₹8.32 | ₹8.55 | ₹46.27 |
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Non-Current Assets | ₹1,496.50 | ₹1,555.95 | ₹1,704.08 | ₹1,697.57 |
| Current Assets | ₹728.60 | ₹790.65 | ₹1,190.87 | ₹1,239.87 |
| Total Assets | ₹2,225.10 | ₹2,346.60 | ₹2,894.95 | ₹2,937.44 |
| Current Liabilities | ₹938.07 | ₹1,237.65 | ₹1,096.12 | ₹1,056.03 |
| Net Current Asset | -₹209.47 | -₹447.00 | ₹94.75 | ₹183.84 |
| Non-Current Liabilities | ₹190.82 | ₹171.53 | ₹295.70 | ₹354.36 |
| Equity Capital | ₹1,096.21 | ₹937.42 | ₹1,503.13 | ₹1,527.05 |
| Total Equity & Liabilities | ₹2,225.10 | ₹2,346.60 | ₹2,894.95 | ₹2,937.44 |
Solara Active Pharma Sciences Limited is an India-based global, pureplay active pharmaceutical ingredients (API) company. The Company is engaged in the manufacturing and development of APIs and offers contract manufacturing and development services for global companies. Its commercial product category includes Albendazole, Aprepitant (Antiemetic), Colchicine, Citicoline Sodium, Disulfiram, Dolutegravir, Etomidate, Flucytosine, Ibuprofen Arginine, Lurasidone Hydrochloride, Rifaximin, Tioconazole, Zileuton and others. Its research and development (R&D) product category includes Brivaracetam, Flecainide Acetate, Naproxen Base, Obeticholic acid, Patiromer Sorbitex Calcium, Rotigotine, Safinamide, Sapropterin, Sugammadex, Tranexamic Acid, Sucroferric Oxyhydroxide and others. Its business is spread across 70 countries with operations in the key markets of North America, Europe, Japan, South Korea and the Middle East and North Africa. It has one R&D center in Chennai.
Solara Active Pharma Sci share price is ₹575.85 as on 03 Jul, 2026, 15:51 IST.
In the last 1 year, Solara Active Pharma Sci delivered a return of -9.55%. The Solara Active Pharma Sci share price hit a high of ₹734.40 and low of ₹422.00.
The Mutual Fund Shareholding in Solara Active Pharma Sci was 1.16% at the end of May 2026.
The 52-week high and low of Solara Active Pharma Sci share is ₹734.40 and ₹422.00 as of 03 Jul, 2026.
The market capitalisation of Solara Active Pharma Sci is ₹2,732.53 Crores as on 03 Jul, 2026.
The stock symbol of Solara Active Pharma Sci is SOLARA on the NSE, 541540 on the BSE, and the ISIN is INE624Z01016.
Solara Active Pharma Sci shares closed yesterday at ₹571.95 on NSE & ₹571.85 on BSE
To buy Solara Active Pharma Sci shares, open a demat account with Upstox and complete the KYC process. Once your account is set up, search for the stock and place your order.
No, shares of Solara Active Pharma Sci or any other publicly traded company cannot be bought or sold on holidays when the stock exchanges are closed. You can only buy or sell Solara Active Pharma Sci shares on days when the stock exchanges are open for trading. It's important to check the NSE & BSE holidays calendar, before placing any trades to avoid any inconvenience.
The PE and PB ratio of Solara Active Pharma Sci is -368.94 and 2.18 respectively, as on 03 Jul, 2026, 15:51 IST.